# Intravitreal Infliximab for Proliferative Vitreoretinopathy

> **NCT04891991** · PHASE2 · COMPLETED · sponsor: **Cairo University** · enrollment: 66 (actual)

## Conditions studied

- Rhegmatogenous Retinal Detachment
- Proliferative Vitreoretinopathy
- Retinal Detachment

## Interventions

- **DRUG:** Intravitreal infliximab
- **PROCEDURE:** Pars plana vitrectomy

## Key facts

- **NCT ID:** NCT04891991
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-26
- **Primary completion:** 2023-11-10
- **Final completion:** 2023-11-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891991, "Intravitreal Infliximab for Proliferative Vitreoretinopathy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04891991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*